Suppr超能文献

鼻咽癌的粒子束治疗:一项系统评价与荟萃分析。

Particle beam therapy for nasopharyngeal cancer: A systematic review and meta-analysis.

作者信息

Ng Wai Tong, But Barton, Wong Charlene H L, Choi Cheuk-Wai, Chua Melvin L K, Blanchard Pierre, Lee Anne W M

机构信息

Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

出版信息

Clin Transl Radiat Oncol. 2022 Aug 23;37:41-56. doi: 10.1016/j.ctro.2022.08.011. eCollection 2022 Nov.

Abstract

BACKGROUND/PURPOSE: A systematic review and meta-analysis were performed to better understand the benefits of particle beam therapy for nasopharyngeal cancer (NPC) treatment. The survival outcomes and toxicity of primary and recurrent NPC patients treated with proton or carbon ion beam therapy were investigated.

METHOD

PubMed, Scopus, and Embase were searched between 1 January 2007 to 3 November 2021. The inclusion and exclusion criteria included studies with either primary or recurrent NPC patients, sample size of ≥10 patients, and proton or carbon ion beam therapy as interventions. Twenty-six eligible studies with a total of 1502 patients were included. We used a random-effect meta-analysis to examine the impact of particle beam therapy on primary NPC patients and qualitatively described the results among recurrent patients. The primary outcome was overall survival (OS), while secondary outcomes included progression-free survival (PFS), local control (LC) and toxicity.

RESULTS

The pooled OS at 1-year, 2-year and 3-year and 5-year for primary NPC patients who received particle beam therapy were 96 % (95 % confidence interval (CI) = 92 %-98 %), 93 % (95 % CI = 83 %-97 %), 90 % (95 % CI = 73 %-97 %) and 73 % (95 % CI = 52 %-87 %) respectively. The pooled 1-year and 2-year PFS, and LC for these patients were above 90 %. For locally recurrent NPC patients, the 1-year OS rate ranged from 65 % to 92 %, while the 1-year LC rate ranged from 80 % to 88 %. Both proton and carbon ion beam therapy were generally safe among primary and recurrent patients, with ≥G3 late toxicity rates of 20 % or less. Approximately a 5 % mortality rate was reported among recurrent patients.

CONCLUSIONS

This systematic review and meta-analysis demonstrated particle beam therapy has great potential in treating NPC, yielding excellent survival outcomes with low toxicity. However, further investigations are needed to assess the long-term outcomes and cost-effectiveness of this newer form of radiotherapy.

摘要

背景/目的:进行了一项系统评价和荟萃分析,以更好地了解粒子束疗法治疗鼻咽癌(NPC)的益处。研究了接受质子或碳离子束疗法治疗的原发性和复发性NPC患者的生存结局和毒性。

方法

检索了2007年1月1日至2021年11月3日期间的PubMed、Scopus和Embase。纳入和排除标准包括涉及原发性或复发性NPC患者的研究、样本量≥10例患者以及以质子或碳离子束疗法作为干预措施的研究。纳入了26项符合条件的研究,共1502例患者。我们使用随机效应荟萃分析来检验粒子束疗法对原发性NPC患者的影响,并定性描述复发性患者的结果。主要结局是总生存期(OS),次要结局包括无进展生存期(PFS)、局部控制(LC)和毒性。

结果

接受粒子束疗法的原发性NPC患者1年、2年、3年和5年的汇总OS分别为96%(95%置信区间(CI)=92%-98%)、93%(95%CI=83%-97%)、90%(95%CI=73%-97%)和73%(95%CI=52%-87%)。这些患者的汇总1年和2年PFS以及LC均高于90%。对于局部复发性NPC患者,1年OS率在65%至92%之间,而1年LC率在80%至88%之间。质子和碳离子束疗法在原发性和复发性患者中总体上都是安全的,≥3级晚期毒性率为20%或更低。复发性患者中报告的死亡率约为5%。

结论

这项系统评价和荟萃分析表明,粒子束疗法在治疗NPC方面具有巨大潜力,能产生优异的生存结局且毒性较低。然而,需要进一步研究来评估这种新型放疗的长期结局和成本效益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e1c/9440257/d28001738586/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验